๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Tarlatamab

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 14 trials in our USA, China, UK and Ireland registers that name Tarlatamab as an intervention. Synced 24 Sep 2026
14Trials tracked
5Recruiting now
2Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Tarlatamab is named as a drug or biological intervention in 14 clinical trials in our USA, China, UK and Ireland trial registers, 5 of which are recruiting. Lead sponsors include Amgen (13) and GlaxoSmithKline (1). Registered phases: Phase 1, Phase 3 and Phase 2. Conditions studied include Small Cell Lung Cancer; Extensive Stage Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC).

01

Clinical trials of Tarlatamab

14 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT07778316 Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) (ClinicalTrials.gov ↗)
Small Cell Lung Cancer
Phase 3 Recruiting Amgen USA, China
NCT06551142 A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) (ClinicalTrials.gov ↗)
Neoplasms
Phase 1 Recruiting GlaxoSmithKline UK, USA
NCT06598306 Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (ClinicalTrials.gov ↗)
Extensive Stage Small Cell Lung Cancer
Phase 1 Recruiting Amgen USA, China
NCT07037758 A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Extensive Stage Small Cell Lung Cancer
Phase 1 Recruiting Amgen USA
NCT07531095 Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (ClinicalTrials.gov ↗)
Small Cell Lung Cancer
Phase 1 Recruiting Amgen USA
NCT05740566 Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (ClinicalTrials.gov ↗)
Small Cell Lung Cancer (SCLC)
Phase 3 Active, closed Amgen Ireland, UK, USA, China
NCT06117774 Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (ClinicalTrials.gov ↗)
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Phase 3 Active, closed Amgen UK, USA, China
NCT06211036 Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (ClinicalTrials.gov ↗)
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Phase 3 Active, closed Amgen Ireland, USA, China
NCT07005128 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (ClinicalTrials.gov ↗)
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Phase 3 Active, closed Amgen USA, China
NCT05060016 A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (ClinicalTrials.gov ↗)
Relapsed/Refractory Small Cell Lung Cancer
Phase 2 Active, closed Amgen UK, USA
NCT06745323 A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (ClinicalTrials.gov ↗)
Small Cell Lung Cancer (SCLC)
Phase 2 Active, closed Amgen UK, USA, China
NCT03319940 Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Small Cell Lung Carcinoma
Phase 1 Active, closed Amgen UK, USA
NCT05361395 First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ClinicalTrials.gov ↗)
Extensive Stage Small Cell Lung Cancer
Phase 1 Active, closed Amgen USA
NCT06898957 Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (ClinicalTrials.gov ↗)
Small Cell Lung Cancer
Phase 1 Active, closed Amgen USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

11 conditions
Condition (as registered)Trials
Small Cell Lung Cancer4
Extensive Stage Small Cell Lung Cancer3
Small Cell Lung Cancer (SCLC)2
Extensive-Stage Small-Cell Lung Cancer1
Small-Cell Lung Cancer1
Small Cell Lung Carcinoma1
Relapsed/Refractory Small Cell Lung Cancer1
Limited Stage Small Cell Lung Cancer1
Neoplasms1
Small-cell Lung Cancer1
Extensive Stage Small-cell Lung Cancer1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Amgen13
GlaxoSmithKline1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Tarlatamab works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tarlatamab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.